source
- FDA approves Mimrylo, a weekly injection for polycythemia vera, developed by Protagonist and sold by TakedaThe Food and Drug Administration has approved a new therapy for polycythemia vera, a rare blood cancer that causes an overproduction of red blood cells. The drug, known as rusfertide, will be mark…
- AstraZeneca’s oral relaxin drug shows partial success in mid-stage heart-failure trialAstraZeneca reported that its oral relaxin agonist improved cardiac function in a subset of patients enrolled in a mid-stage heart‑failure study. The trial demonstrated measurable benefits for some…